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disease (AD) is the most common cause of dementia and there is no
cure. The cost to the American public for treating AD is currently estimat-
ed at $214 billion per year, a concerning statistic given that the disease
population is expected to quadruple by 2050 (Holtzman et al., 2011).
By 2030, it is estimated that the global burden of ADwill reach $1 trillion
USD, which does not take into account the emotional, physical, and ﬁ-
nancial burden of unpaid caregivers. Although these estimations suggest
a bleak horizon for AD patients, caregivers, and their families, great
strides in basic research and translational neuroscience in recent years
offer new hope for those suffering from this debilitating disease.
There is a unique set of challenges that face researchers when con-
sidering how to approach therapeutic intervention for AD. First, the
pathological changes that ultimately lead to cognitive decline and de-
mentia begin to accumulate well before symptoms become evident.
The two primary pathologies in AD include plaques, extracellular aggre-
gates of the amyloid-beta (Aβ) peptide, and tangles which refer to the
intracellular accumulation of aggregated forms of the tau protein. Ac-
cording to the amyloid hypothesis (Hardy and Selkoe, 2002),
10–15 years prior to the onset of dementia, Aβ begins to accumulate
within speciﬁc regions of the brain and form amyloid plaques. Plaque
growth peaks and plateaus just after the onset of clinical symptoms. Ag-
gregated, hyperphosphorylated tau, a marker of neurodegeneration,
also begins to accumulate during this pre-symptomatic period. Tau ac-
cumulation appears to occur in regions which also have decreased
brain volume, synaptic integrity, and glucose metabolism. By the time
patients manifest signs of dementia, the pathogenesis of AD is ﬁrmly
established within the brain and therefore the most effective treatment
for ADmust not only stop disease progression but must also reverse de-
cades of damage coinciding with Aβ and tau aggregation. Also by the
time of diagnosis, Aβ and tau, which appear to be the primary instiga-
tors of disease, have initiated a deleterious cascade of secondary disease
mechanisms, such as metabolic dysfunction, oxidative stress, and neu-
roinﬂammation, which are as equally pernicious to the brain as the pri-
mary insult itself. To date, most treatment strategies have tried to target
the production or clearance of Aβ or manipulate tau aggregation, while
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the complexity and heterogeneity of disease mechanisms at play in AD.
Although targeting plaques and tangles will most likely be integral to
any successful treatment strategy for AD, there are other biological pro-
cesses, such as neuroinﬂammation, that require equal consideration as
researchers move forward toward a holistic and efﬁcacious treatment
for AD. Moreover, early intervention, most likely during the pre-
symptomatic period is a likely necessity for the most successful treat-
ment of AD.
There have been some important new ﬁndings over the last year and
a few are highlighted here. One issue that has plagued the AD ﬁeld is the
lack of in vitro or in vivo systems thatmimic all aspects of the humandis-
ease. Approximately 20 years ago (Scheuner et al., 1996), several muta-
tions in the genes encoding amyloid precursor protein (APP) and
presenilin (PSEN) were discovered to give rise to early-onset familial
AD (FAD) through the increased production of the plaque forming
peptide, Aβ. Mouse models harboring these human mutations were
generated but fail to fully recapitulate humanAD. In particular, the over-
expression of mutant APP and PSEN1 leads to increased Aβ and plaque
formation, yet little to no tau pathology is present in these models. Sim-
ilarly, models that overexpress mutant forms of human microtubule-
associated protein tau display hyperphosphorylated, insoluble tau but
lack any appreciable amyloid pathology. Therefore, preclinical studies
investigating therapeutic efﬁcacy occurred in models lacking the full
breadth of clinical disease, which could be one explanation for why
these therapies fail to translate to efﬁcacy in Phase III clinical trials. With
the recent publication byKim, Tanzi, and colleagues inNature, the authors
describe the ﬁrst of its kind in vitromodel of AD (Choi et al., 2014). By in-
troducing FAD mutations in human neuronal progenitor cells cultured in
a three dimensional gelatin matrix, the authors were able to recapitulate
both extracellular amyloid plaque pathology as well as intracellular accu-
mulation of aggregated, hyperphosphorylated tau protein, mimicking
more closely the pathogenesis of AD in a dish. Not only does this novel
3D culture system provide researchers with a unique opportunity to
study the evolution of AD pathology, it provides a tremendous opportuni-
ty for high throughout screening of potential drug candidates that can
ameliorate both plaque and tangle pathology. Given the investment of
time and resources typically involved in drug development and clinical
trials, this new techniquemight offer amore rapid, streamlined approach
to candidate selection.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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gy in a dish, the ﬁndings by Kim, Tanzi, and colleagues also re-empha-
size the importance of exploring the genetics underlying AD. Although
many FAD mutations in APP and PSEN1 have been well-characterized
over the past 20 years, the advent of more sophisticated sequencing
techniques allows for the identiﬁcation of an inﬁnite number of genetic
changes associated with AD which could not only give insight into dis-
ease pathogenesis but also identify novel therapeutic candidates.
Genome-wide association studies (GWAS) have identiﬁed at least 20
new loci involved in the increased risk for developing AD (Karch et al.,
2014). For example, recent whole-exome and whole-genome wide se-
quencing strategies identiﬁed mutations in the TREM2 gene as confer-
ring an increased risk for AD by 3.4-fold (Guerreiro et al., 2013;
Jonsson et al., 2013). TREM2, or triggering receptor expressed on mye-
loid cells 2, is a transmembrane protein expressed by myeloid cells, in-
cluding microglia and peripheral monocytes. Although endogenous
ligands for TREM2 remain unknown, TREM2 regulates phagocytosis
and the neuroinﬂammatory response to pathology within the brain.
The identiﬁcation of TREM2 mutations provides further conﬁrmation
that neuroinﬂammation, speciﬁcally microglial activation, is a signiﬁ-
cant component of AD pathogenesis and is an important component
of the comprehensive treatment of AD. Although the role of TREM2 ex-
pression onmicroglial function in the context of Aβ and tau is still up for
debate (Ulrich et al., 2014; Melchior et al., 2010; Kleinberger et al.,
2014), the importance of GWAS for furthering both the basic under-
standing of AD aswell as the importance in elucidating new therapeutic
avenues to pursue is unequivocal.
Tremendous strides in working toward the goal of an Alzheimer's
therapeutic have been uncovered by fundamental scientiﬁc research.
By identifying the timeline of pathological changes in the AD brain, re-
searchers can make more informed decisions on clinical trial design
and therapeutic interventions. Development of novel basic science
tools, such as the human neural stem-cell-derived 3D culture system,
provides an unprecedented newway for studying pathological interac-
tions while simultaneously providing a high throughput screen for pos-
sible drug candidates in AD. Using GWAS as a basic method to
understand individual risk for developing AD also provides researchers
with druggable targets and amore comprehensive understanding of the
cascade of disease processes. Taken together, basic and translational sci-
entists are working in concert to bring about changes in the ﬁeld of AD
therapeutics.Conﬂicts of Interest
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